Rare Autoinflammatory Diseases Drug Market

The Rare Autoinflammatory Diseases Drug Market is projected to reach USD 4.13 Billion in 2026. It is expected to continue growing at a CAGR of 9.70%, reaching USD 7.23 Billion by 2032.

Rare Autoinflammatory Diseases Drug Market: Executive Overview

Rare autoinflammatory diseases are driven primarily by dysregulated innate immunity and include conditions such as cryopyrin-associated periodic syndromes, familial Mediterranean fever, mevalonate kinase deficiency, and systemic juvenile idiopathic arthritis. Drug development and access are shaped by small patient populations, heterogeneous presentation, delayed diagnosis, specialist dependence, and the need to demonstrate meaningful control of recurrent inflammation and organ damage.

The treatment environment combines targeted biologics, immunomodulatory therapies, supportive care, and disease-specific management. Regulatory incentives for rare diseases, advances in molecular diagnosis, and growing awareness of untreated inflammatory burden are improving development opportunities, while evidence generation, manufacturing complexity, reimbursement, and equitable access remain central challenges.

From Symptom Control to Precision, Long-Term Disease Management

The landscape is shifting from broad suppression of inflammation toward mechanism-informed treatment. Greater recognition of cytokine pathways, genetic drivers, and phenotype differences is supporting more precise therapy selection and encouraging clinical programs that evaluate sustained remission, flare prevention, quality of life, and preservation of organ function rather than short-term symptom reduction alone.

Care delivery is also becoming more coordinated. Multidisciplinary specialty centers, patient registries, molecular testing, and remote monitoring can help shorten diagnostic journeys and identify treatment response earlier. However, limited natural-history data and small trial populations continue to make endpoint selection, comparator choice, and long-term safety assessment difficult.

Artificial Intelligence Strengthens Diagnosis, Evidence Generation, and Care Coordination

Artificial intelligence can support rare autoinflammatory disease care by identifying diagnostic patterns across clinical records, laboratory results, imaging, and genetic data. Properly validated tools may help prioritize patients for specialist review, detect potential flares, and distinguish overlapping inflammatory phenotypes. These applications should augment clinicians rather than replace specialist judgment, particularly where symptoms are nonspecific and training data are limited.

In research, AI can assist with cohort discovery, trial feasibility, biomarker analysis, protocol design, and adverse-event surveillance. Its value depends on representative datasets, transparent validation, privacy safeguards, and clear accountability. Because rare-disease datasets are small and vulnerable to bias, external validation and continuous performance monitoring are essential before deployment.

Regional Priorities Differ Across North America, Latin America, Europe, Middle East, Africa, and Asia-Pacific

North America generally benefits from specialized centers, rare-disease research networks, and established pathways for orphan-drug review, although coverage restrictions and uneven access can delay treatment. Europe has strong regulatory and reference-network infrastructure, but national health-technology assessment, reimbursement, and cross-border care requirements create variation among countries. Asia-Pacific combines advanced specialist capacity in several health systems with substantial differences in diagnosis, genetic testing, and access across urban and rural settings.

Latin America faces persistent diagnostic delays, uneven specialist distribution, and budget constraints, while regional registries and collaborative centers can improve evidence and referral pathways. In the Middle East, concentrated tertiary care and growing genomic capabilities coexist with variable reimbursement and fragmented patient identification. Africa requires stronger laboratory infrastructure, specialist training, referral systems, and locally relevant evidence to address underdiagnosis and treatment inequity.

ASEAN, BRICS, European Union, G7, GCC, and NATO Require Differentiated Access Strategies

ASEAN markets share opportunities for pooled expertise, regional referral networks, and harmonized approaches to rare-disease diagnosis, but differ substantially in regulatory maturity and reimbursement. BRICS members offer large clinical and genetic diversity alongside wide variation in infrastructure, affordability, and specialist access. The European Union benefits from collaborative reference networks and shared rare-disease initiatives, while national reimbursement decisions still determine practical availability.

G7 systems tend to have stronger research capacity, pharmacovigilance, and specialist services, but face scrutiny over value, affordability, and health-system sustainability. GCC countries often have concentrated tertiary infrastructure and interest in genomic medicine, with access shaped by public funding and referral arrangements. NATO members span diverse health systems; preparedness, interoperable health information, and cross-border research collaboration can support more resilient rare-disease care.

Country-Level Priorities Span Innovation Leadership, Diagnostic Capacity, and Access Equity

Australia combines advanced clinical research with geographic access challenges, making telehealth and coordinated referral important. Brazil and Mexico must address regional disparities, specialist shortages, and public-system access while strengthening rare-disease registries. Canada and the United States have substantial specialist and research capacity, but patients may encounter payer, geography, and prior-authorization barriers. China and India offer expanding biotechnology and clinical capabilities, alongside major differences between metropolitan and rural care.

France, Germany, Italy, Spain, and the United Kingdom have established rare-disease expertise and structured regulatory or health-system pathways, though reimbursement and service organization vary. Japan and South Korea have strong medical infrastructure and growing precision-medicine capabilities, with demographic and policy considerations influencing care delivery. Russia faces challenges related to geographic scale, specialized access, and continuity of supply. Across all countries, earlier diagnosis, reliable patient identification, and sustained treatment monitoring remain shared priorities.

Industry Leaders Should Build Evidence, Access, and Partnerships Around Patient Outcomes

Leaders should prioritize mechanism-aligned development programs with clinically meaningful endpoints, robust natural-history studies, and long-term follow-up. Patient registries, genetic characterization, validated biomarkers, and interoperable real-world data can improve trial recruitment and clarify treatment durability without compromising privacy. Development plans should also anticipate pediatric needs, pregnancy considerations where relevant, immunogenicity, infection risk, and organ-specific outcomes.

Commercial and access strategies should be tailored to national health systems rather than treated as uniform globally. Practical priorities include early dialogue with regulators and payers, transparent value communication, diagnostic education, specialist-network development, patient-support services, and resilient manufacturing and distribution. Partnerships with clinicians, patient organizations, laboratories, and public-health institutions can improve identification of undiagnosed patients and ensure that innovation translates into equitable care.

Methodology: Evidence Triangulation Across Biology, Care Pathways, and Health Systems

This executive summary uses a structured qualitative synthesis of established disease biology, clinical-management principles, rare-disease policy considerations, diagnostic developments, and health-system characteristics relevant to rare autoinflammatory diseases. Analysis is organized across the required regions, country groupings, and countries, with emphasis on verifiable patterns rather than numerical market claims.

Interpretation should be supported by peer-reviewed literature, regulatory and health-technology assessment publications, clinical guidelines, disease registries, public reimbursement documents, and recognized epidemiological or genetic databases. Because patient populations are small and reporting practices differ, findings should be refreshed as new clinical evidence, regulatory decisions, safety information, and access policies emerge.

Conclusion: Sustainable Progress Depends on Earlier Diagnosis and Equitable Precision Care

Rare autoinflammatory disease drug development is advancing toward targeted, durable, and patient-centered management, but scientific progress alone will not resolve diagnostic delay or unequal access. The most effective strategies combine molecular understanding with practical referral systems, validated outcomes, coordinated specialty care, and long-term safety monitoring.

Across regions, groups, and countries, leaders can create durable value by strengthening evidence infrastructure, integrating responsible AI, supporting clinicians and patients, and aligning innovation with health-system affordability and implementation capacity. Success should be judged by earlier diagnosis, fewer inflammatory flares, protection from cumulative damage, improved quality of life, and dependable access for patients with these rare conditions.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rare Autoinflammatory Diseases Drug Market, by Drug Class

7.1. Introduction
7.2. Biologics
7.2.1. Il-1 Inhibitors
7.2.2. Il-6 Inhibitors
7.2.3. Tnf Inhibitors
7.3. Corticosteroids
7.4. Small Molecule Inhibitors

8. Rare Autoinflammatory Diseases Drug Market, by Route Of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous

9. Rare Autoinflammatory Diseases Drug Market, by Indication

9.1. Introduction
9.2. Cryopyrin-Associated Periodic Syndromes
9.2.1. Familial Cold Autoinflammatory Syndrome
9.2.2. Muckle-Wells Syndrome
9.2.3. Neonatal-Onset Multisystem Inflammatory Disease
9.3. Familial Mediterranean Fever
9.4. Hyperimmunoglobulin D Syndrome
9.5. Tumor Necrosis Factor Receptor Associated Periodic Syndrome

10. Rare Autoinflammatory Diseases Drug Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy

11. Rare Autoinflammatory Diseases Drug Market, by End User

11.1. Introduction
11.2. Adult Patients
11.3. Geriatric Patients
11.4. Pediatric Patients

12. Rare Autoinflammatory Diseases Drug Market, by Region

12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa

13. Rare Autoinflammatory Diseases Drug Market, by Group

13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO

14. Rare Autoinflammatory Diseases Drug Market, by Country

14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. AB2 Bio Ltd
16.2. ACELYRIN, Inc.
16.3. Aslan Pharmaceuticals Limited
16.4. BioCryst Pharmaceuticals, Inc.
16.5. CSL Behring GmbH
16.6. Humanigen, Inc.
16.7. Immedica Pharma AB
16.8. Inmagene Biopharmaceuticals
16.9. Janssen Biotech, Inc.
16.10. Kiniksa Pharmaceuticals, Ltd.
16.11. Mabpharm Limited
16.12. Novartis AG
16.13. Pharming Group N.V.
16.14. Regeneron Pharmaceuticals, Inc.
16.15. RPharm
16.16. Swedish Orphan Biovitrum AB
16.17. Takeda Pharmaceutical Company Limited
16.18. Zydus Lifesciences Limited

17. Key Experts

LIST OF FIGURES

FIGURE 1. Global Rare Autoinflammatory Diseases Drug Market, Years Considered for the Study
FIGURE 2. Global Rare Autoinflammatory Diseases Drug Market, Research Design
FIGURE 3. Global Rare Autoinflammatory Diseases Drug Market, Research Framework
FIGURE 4. Global Rare Autoinflammatory Diseases Drug Market, Data Triangulation
FIGURE 5. Global Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Rare Autoinflammatory Diseases Drug Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Rare Autoinflammatory Diseases Drug Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Rare Autoinflammatory Diseases Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Rare Autoinflammatory Diseases Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Rare Autoinflammatory Diseases Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Rare Autoinflammatory Diseases Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Rare Autoinflammatory Diseases Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Rare Autoinflammatory Diseases Drug Market Share, by Key Player, 2025

LIST OF TABLES

TABLE 1. Global Rare Autoinflammatory Diseases Drug Market Segmentation & Coverage
TABLE 2. Global Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Il-1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Il-1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Il-1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Il-6 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Il-6 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Il-6 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Tnf Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Tnf Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Tnf Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Small Molecule Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Small Molecule Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Small Molecule Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 33. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Familial Cold Autoinflammatory Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Familial Cold Autoinflammatory Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Familial Cold Autoinflammatory Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Muckle-Wells Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Muckle-Wells Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Muckle-Wells Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Neonatal-Onset Multisystem Inflammatory Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Neonatal-Onset Multisystem Inflammatory Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Neonatal-Onset Multisystem Inflammatory Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Familial Mediterranean Fever Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Familial Mediterranean Fever Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Familial Mediterranean Fever Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Hyperimmunoglobulin D Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hyperimmunoglobulin D Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hyperimmunoglobulin D Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Tumor Necrosis Factor Receptor Associated Periodic Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Tumor Necrosis Factor Receptor Associated Periodic Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Tumor Necrosis Factor Receptor Associated Periodic Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 55. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Global Adult Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Adult Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Adult Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Geriatric Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Geriatric Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Geriatric Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Pediatric Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Pediatric Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Pediatric Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. North America Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. North America Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 85. North America Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 86. North America Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 87. North America Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. North America Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 89. North America Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. North America Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 93. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 94. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 95. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 97. Latin America Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Latin America Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Europe Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Europe Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 101. Europe Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 102. Europe Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. Europe Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. Europe Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 105. Europe Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Europe Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 109. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 110. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 111. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 113. Middle East Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Middle East Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. Africa Rare Autoinflammatory Diseases Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Africa Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 117. Africa Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 118. Africa Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 119. Africa Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. Africa Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 121. Africa Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Africa Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. Global Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 126. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 127. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 129. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 130. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. ASEAN Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. GCC Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. GCC Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 134. GCC Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 135. GCC Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 136. GCC Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. GCC Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 138. GCC Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. GCC Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. European Union Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. European Union Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 142. European Union Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 143. European Union Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 144. European Union Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. European Union Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 146. European Union Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. European Union Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 150. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 151. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 154. BRICS Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. BRICS Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. G7 Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. G7 Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 158. G7 Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 159. G7 Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 160. G7 Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. G7 Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 162. G7 Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. G7 Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. NATO Rare Autoinflammatory Diseases Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. NATO Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 166. NATO Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 167. NATO Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 168. NATO Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 169. NATO Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 170. NATO Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. NATO Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Global Rare Autoinflammatory Diseases Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. United States Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 174. United States Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 175. United States Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 176. United States Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. United States Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. United States Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 179. United States Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. United States Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Canada Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 182. Canada Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 183. Canada Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 184. Canada Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. Canada Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 186. Canada Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 187. Canada Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Canada Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. Mexico Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 190. Mexico Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 191. Mexico Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 192. Mexico Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 193. Mexico Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. Mexico Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 195. Mexico Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Mexico Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Brazil Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 198. Brazil Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 199. Brazil Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 200. Brazil Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. Brazil Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. Brazil Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 203. Brazil Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Brazil Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 206. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 207. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 208. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 210. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 211. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. United Kingdom Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. Germany Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 214. Germany Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 215. Germany Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 216. Germany Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. Germany Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 218. Germany Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 219. Germany Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Germany Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. France Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 222. France Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 223. France Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 224. France Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 225. France Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. France Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 227. France Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. France Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Russia Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 230. Russia Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 231. Russia Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 232. Russia Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 233. Russia Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. Russia Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 235. Russia Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Russia Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Italy Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 238. Italy Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 239. Italy Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 240. Italy Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 241. Italy Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. Italy Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 243. Italy Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Italy Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. Spain Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 246. Spain Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 247. Spain Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 248. Spain Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 249. Spain Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. Spain Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 251. Spain Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Spain Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. China Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 254. China Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 255. China Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 256. China Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 257. China Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. China Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 259. China Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. China Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. India Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 262. India Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 263. India Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 264. India Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 265. India Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 266. India Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 267. India Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. India Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Japan Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 270. Japan Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 271. Japan Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 272. Japan Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 273. Japan Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 274. Japan Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 275. Japan Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 276. Japan Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. Australia Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 278. Australia Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 279. Australia Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 280. Australia Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 281. Australia Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 282. Australia Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 283. Australia Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. Australia Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 285. South Korea Rare Autoinflammatory Diseases Drug Market Size, 2017-2032 (USD Million)
TABLE 286. South Korea Rare Autoinflammatory Diseases Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 287. South Korea Rare Autoinflammatory Diseases Drug Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 288. South Korea Rare Autoinflammatory Diseases Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 289. South Korea Rare Autoinflammatory Diseases Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 290. South Korea Rare Autoinflammatory Diseases Drug Market Size, by Cryopyrin-Associated Periodic Syndromes, 2017-2032 (USD Million)
TABLE 291. South Korea Rare Autoinflammatory Diseases Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 292. South Korea Rare Autoinflammatory Diseases Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. Global Rare Autoinflammatory Diseases Drug Market Share, by Key Player, 2025
TABLE 294. Global Rare Autoinflammatory Diseases Drug Market, Key Experts

Companies Mentioned

AB2 Bio Ltd
ACELYRIN, Inc.
Aslan Pharmaceuticals Limited
BioCryst Pharmaceuticals, Inc.
CSL Behring GmbH
Humanigen, Inc.
Immedica Pharma AB
Inmagene Biopharmaceuticals
Janssen Biotech, Inc.
Kiniksa Pharmaceuticals, Ltd.
Mabpharm Limited
Novartis AG
Pharming Group N.V.
Regeneron Pharmaceuticals, Inc.
RPharm
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Company Limited
Zydus Lifesciences Limited

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3209EUR$3,545USD£2,754GBP €3566EUR$3,939USD£3,060GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4855EUR$5,363USD£4,167GBP €5395EUR$5,959USD£4,630GBP

Rare Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032